Results 161 to 170 of about 40,669 (305)

Chimeric Antigen Receptor T‐Cells in Myasthenia Gravis: Advances, Safety Challenges, and Future Directions

Muscle &Nerve, Volume 73, Issue 6, Page 942-951, June 2026.
ABSTRACT This review examines the emerging application of chimeric antigen receptor (CAR) T‐cell therapy in myasthenia gravis (MG), with emphasis on safety, efficacy signals, and future therapeutic potential in treatment‐refractory disease. A comprehensive literature search was conducted across PubMed, medRxiv, bioRxiv, and Google Scholar for studies ...
Tobias Hegelmaier, Alexander Duscha, Christiane Desel, Sarah Stassen, Tim Krzemien, Ann‐Katrin Hennemann, Vaia Pappa, Aiden Haghikia   +7 more
wiley   +1 more source

A large-scale comparison of clinical outcomes to IBD therapies in White and South Asian ethnicities. [PDF]

EClinicalMedicine
Balarajah S, Martinez-Gili L, Alexander JL, Mullish BH, Perry RW, Li JV, Marchesi JR, Parkes M, Orchard TR, Hicks LC, Williams HRT, UK IBD BioResource Investigators.   +11 more
europepmc   +1 more source

Clinical dilemma of mood stabilizer augmentation in treatment‐resistant schizophrenia with residual phase: A case report of valproate‐associated hypoglycemia and cytopenia, and subsequent lithium response

Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 2, June 2026.
Abstract Background Mood stabilizer augmentation is frequently used in treatment‐resistant schizophrenia despite limited guideline recommendations. Evidence for its efficacy and safety in the residual phase, however, remains insufficient. Case Presentation A 49‐year‐old Japanese woman with treatment‐resistant residual schizophrenia exhibited persistent
Yoshiki Kasagi, Naomichi Okamoto, Reiji Yoshimura   +2 more
wiley   +1 more source

Prevalence and determinants of microbiologically unconfirmed healthcare-associated infections among hospitalized patients in Western Sierra Leone, 2024: a point prevalence survey. [PDF]

Infect Prev Pract
Fofanah BD, Kamara IF, Kamara RZ, Musoke R, Nuwagira IB, Ngauja RE, Ellie E, Tengbe SM, Sandy SFF, Williams RE, Bangura IA, Mansaray AR, Kabego L, Lakoh S.   +13 more
europepmc   +1 more source

What Is Your Diagnosis? Abnormal WDF Scattergram From the Sysmex XN‐1000V in a Cat

Veterinary Clinical Pathology, EarlyView.
Javier Martínez‐Caro, Laura Chaves‐Falcón, Marta Lemos, Xavier Roura, Luis Bosch, Josep Pastor   +5 more
wiley   +1 more source

Age‐Dependent Differences in Canakinumab Safety: A Comprehensive Pharmacovigilance Analysis Using the FAERS Database

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT While the efficacy of canakinumab, an anti‐interleukin‐1β monoclonal antibody, is well‐established, its safety profile, particularly across different age groups, remains inadequately explored. Using the FDA Adverse Event Reporting System (FAERS) database, this study evaluated postmarketing safety by analyzing adverse event (AE) reports from ...
Youyang Wang, Ngasin Lam, Xiaoming Huang, Yang Jiao   +3 more
wiley   +1 more source

Efficacy and safety of neoadjuvant chemotherapy combined with concurrent chemoradiotherapy and concurrent chemoradiotherapy alone in locally advanced cervical cancer: a systematic review and meta-analysis. [PDF]

Transl Cancer Res
Lu Y, Zhao J, Jia Z, Zhang C.
europepmc   +1 more source

Successful in vitro propagation of feline coronavirus from clinically diagnosed feline infectious peritonitis cases using Vero cells: A potential model for future research

Veterinary Record Open, Volume 13, Issue 1, June 2026.
Abstract Background Feline coronavirus (FCoV) causes inapparent to progressive fatal feline infectious peritonitis (FIP) in domestic and wild cats, which affects multiple‐organ systems. Methods We investigated three clinically sick cats using different laboratory and molecular tests to diagnose and confirm FCoV and propagate the virus in Vero cell ...
Eaftekhar Ahmed Rana, Mahfuza Akther, Susan Beetson, Subir Sarker, Gabriele Rossi, Jasim M. Uddin   +5 more
wiley   +1 more source

[Probable neutropenia secondary to treatment with rifampicin]. [PDF]

Rev Esp Quimioter
España-Marí G, Álvarez-Arroyo L, Alentado-Mateu A, Limón-Ramírez R, Montañés-Pauls B.   +4 more
europepmc   +1 more source

Leucopenia and indomethacin. [PDF]

BMJ, 1966
openaire   +2 more sources